# **Detection of ALK and ROS1 Rearrangements Using Next Generation Sequencing in Lung Cancer:** Comparison between FISH, IHC and NGS

Sergi Clavé<sup>1,2</sup>, Natalia Rodon<sup>3</sup>, Lara Piluan<sup>1,2</sup>, Alba Dalmases<sup>1,2</sup>, Olga Díaz<sup>3</sup>, Álvaro Taus<sup>2,4</sup>, Marta Lorenzo<sup>1,2</sup>, Pedro Rocha<sup>2,4</sup>, Ana M Muñoz Mármol<sup>5</sup>, Glòria Oliveras<sup>6</sup>, Joaquim Bosch-Barrera<sup>6</sup>, Blanca Espinet<sup>1,2</sup>, Beatriz Bellosillo<sup>1,2</sup>, Xayler Puig<sup>3</sup>, Edume Arriola<sup>2,4</sup>, and Marta Salido<sup>1,2</sup>

> 1. Pathology Department, Hospital del Mar, Barcelona, Spain. 2. Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. 3. BIOPAT Biopatología Molecular S.L., Grup Assistència, Barcelona, Spain. 4. Medical Oncology Department, Hospital del Mar, Barcelona, Spain. 5. Pathology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. 6. Medical Oncology Department, Catalan Institute of Oncology (ICO), Girona, Spain.

> > Disclosures: The authors of this abstract have declared no conflicts of interest.

Contact: sclave@imim.es


### **BACKGROUND**

- Detection of ALK and ROS1 rearrangements in non-small cell lung cancer (NSCLC) is required for directing patient care. ■ While fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) have been established as gold standard methods, next generation sequencing (NGS) platforms are called to be at least equally successful, but also more compatible with multiplexing and diagnostic workflows.
- Our aim was to investigate the performance of NGS in the detection of rearranged cases.

# DESIGN

Forty-two NSCLC samples were selected retrospectively from our database (n= 3.360) based on previous ALK (n= 34) and ROS1 (n= 8) FISH results (positive or inconclusive) and material availability (Figure 1).

Cases were tested by both FISH (Abbott Molecular) and IHC (Ventana) in paraffin blocks, and were reviewed centrally to determine the tumor area. DNA and RNA were manually extracted from paraffin sections. Ion Torrent sequencing technology with Oncomine™ Focus Assay (Thermo Fisher Scientific) were applied using 10ng DNA and 100ng RNA from each sample (Figure 2).



been testing NSCLC samples as a referral center since 2011. We screened all samples by FISH with break-apart probes.



Figure 2. Oncomine the Focus Assay workflow. Paraffin blocks were re-evaluated to ensure the minimum tumor area and percentage of infiltration, DNA and RNA were isolated using RecoverAll Total Nucleic Acid Isolation Kit for FFPE and 10ng DNA and 100ng RNA were used to perform Oncomine To Focus Assay (Thermo Fisher Scientific).

## RESULTS

Patient's characteristics were median age 60 years, 52% males, and 83% diagnosed as adenocarcinoma (ADC). Regarding FISH results, 18 cases had solit signals, 21 had isolated 3' signals, and three had negative FISH pattern with isolated 5' signals (Figure 1). Testing with IHC, nine out of

the 42 cases were negative: the three isolated 5' FISH negative and six isolated 3' FISH positive cases (discordance FISH vs. IHC) (Figure 3). NGS technology detected positive ALK and ROS1 fusions in 82% of the assessable samples (27/33), being EML4(13)-ALK(20) and EZR(10)-ROS1(34) the most prevalent (Figure 4). Nine cases (21%) were non-evaluable by NGS due to insufficient sequencing coverage (seven were small biopsies with low RNA input).

Regarding the six cases with negative NGS result: three were the isolated 5' FISH negative cases in accordance with negative IHC, and the other three presented isolated 3' FISH positive pattern, negative by IHC (Figure 5).



Figure 3. Comparison between FISH, IHC and NGS, Cases with ALK or ROS1 positive FISH split signals were all pos ed to those considered FISH positive with 3' isolated signals.





Figure 5. Discordant 3' isolated FISH positive cases. These cases potentially indicate a FISH false-pr its. Both IHC and NGS are valid alternative tests to check these alterations



EML4(13)-ALK(20) and EZR(10)-ROS1(34) fusions warn the most prevalent Remarkably, there were those ALK rearranged cases without partner defined (imbalance 31/51).

### CONCLUSIONS

- NGS technology for detecting ALK and ROS1 rearrangements in NSCLC could be considered as a screening test although the success rate is closely related to the correct evaluation of the initial amount of tumor tissue, particularly in small biopsies.
- The discordance observed in the isolated 3' FISH positive cases potentially indicates that this alteration could be a FISH false-positive result. NGS technology could be used as an additional molecular technique for cases with inconclusive or discordant FISH/IHC results.



